Cite
HARVARD Citation
Fernandez, A. et al. (2022). Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5‐year data from reSURFACE 1 and reSURFACE 2. Journal of the European Academy of Dermatology and Venereology. pp. 1774-1783. [Online].